{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:58:17Z","timestamp":1777111097632,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T00:00:00Z","timestamp":1158019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T00:00:00Z","timestamp":1158019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2007,6,1]]},"DOI":"10.1038\/sj.tpj.6500410","type":"journal-article","created":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T16:12:05Z","timestamp":1158077525000},"page":"200-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Genetic variation at the CYP2C locus and its association with torsemide biotransformation"],"prefix":"10.1038","volume":"7","author":[{"given":"S V","family":"Vormfelde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M R","family":"Toliat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Meineke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kirchheiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"N\u00fcrnberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Brockm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,9,12]]},"reference":[{"key":"BF6500410_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","volume":"45","author":"JO Miners","year":"1998","unstructured":"Miners JO, Birkett DJ . Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525\u2013538.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500410_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1517\/17410541.1.1.63","volume":"1","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Tsahuridu MWJ, Roots I, Brockm\u00f6ller J . The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Personalized Med 2004; 1: 63\u201384.","journal-title":"Personalized Med"},{"key":"BF6500410_CR3","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR . Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211\u20132221.","journal-title":"N Engl J Med"},{"key":"BF6500410_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","volume":"77","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Brockm\u00f6ller J . Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1\u201316.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500410_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.clpt.2004.12.267","volume":"77","author":"RA Totah","year":"2005","unstructured":"Totah RA, Rettie AE . Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77: 341\u2013352.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500410_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1081\/DMR-120001392","volume":"34","author":"S Rendic","year":"2002","unstructured":"Rendic S . Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34: 83\u2013448.","journal-title":"Drug Metab Rev"},{"key":"BF6500410_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1600-0773.2004.pto950102.x","volume":"95","author":"U Klotz","year":"2004","unstructured":"Klotz U, Schwab M, Treiber G . CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"BF6500410_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.mp.4001494","volume":"9","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442\u2013473.","journal-title":"Mol Psychiatry"},{"key":"BF6500410_CR9","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1021\/tx050181o","volume":"18","author":"RT Kinobe","year":"2005","unstructured":"Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM . P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol 2005; 18: 1868\u20131875.","journal-title":"Chem Res Toxicol"},{"key":"BF6500410_CR10","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM de Morais","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419\u201315422.","journal-title":"J Biol Chem"},{"key":"BF6500410_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1124\/jpet.105.091181","volume":"315","author":"TC DeLozier","year":"2005","unstructured":"DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA . Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005; 315: 1085\u20131090.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6500410_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1124\/jpet.104.067819","volume":"310","author":"TC DeLozier","year":"2004","unstructured":"DeLozier TC, Tsao CC, Coulter SJ, Foley J, Bradbury JA, Zeldin DC et al. CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 2004; 310: 845\u2013854.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6500410_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.clpt.2005.01.019","volume":"77","author":"DL Veenstra","year":"2005","unstructured":"Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77: 353\u2013364.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500410_CR14","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1182\/blood-2003-07-2521","volume":"103","author":"H Takahashi","year":"2004","unstructured":"Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S et al. 5\u2032-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103: 3055\u20133057.","journal-title":"Blood"},{"key":"BF6500410_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1067\/mcp.2001.117367","volume":"70","author":"M Shintani","year":"2001","unstructured":"Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N et al. Genetic polymorphisms and functional characterization of the 5\u2032-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 2001; 70: 175\u2013182.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500410_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/nature01140","volume":"419","author":"PC Sabeti","year":"2002","unstructured":"Sabeti PC, Reich DE, Higgins JM, Levine HZ, Richter DJ, Schaffner SF et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 2002; 419: 832\u2013837.","journal-title":"Nature"},{"key":"BF6500410_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00439-005-0090-0","volume":"119","author":"EC Walsh","year":"2006","unstructured":"Walsh EC, Sabeti P, Hutcheson HB, Fry B, Schaffner SF, de Bakker PI et al. Searching for signals of evolutionary selection in 168 genes related to immune function. Hum Genet 2006; 119: 92\u2013102.","journal-title":"Hum Genet"},{"key":"BF6500410_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/01.fpc.0000182779.03180.ba","volume":"16","author":"M Schirmer","year":"2006","unstructured":"Schirmer M, Toliat MR, Haberl M, Suk A, Kamdem LK, Klein K et al. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet Genomics 2006; 16: 59\u201371.","journal-title":"Pharmacogenet Genomics"},{"key":"BF6500410_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00008571-200004000-00008","volume":"10","author":"JO Miners","year":"2000","unstructured":"Miners JO, Coulter S, Birkett DJ, Goldstein JA . Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 2000; 10: 267\u2013270.","journal-title":"Pharmacogenetics"},{"key":"BF6500410_CR20","first-page":"1076","volume":"272","author":"JO Miners","year":"1995","unstructured":"Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ . Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995; 272: 1076\u20131081.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6500410_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.clpt.2004.08.024","volume":"76","author":"SV Vormfelde","year":"2004","unstructured":"Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther 2004; 76: 557\u2013566.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500410_CR22","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1021\/bi0496844","volume":"43","author":"O Kerdpin","year":"2004","unstructured":"Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, Miners JO . Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry 2004; 43: 7834\u20137842.","journal-title":"Biochemistry"},{"key":"BF6500410_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00008571-200203000-00004","volume":"12","author":"J Kirchheiner","year":"2002","unstructured":"Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101\u2013109.","journal-title":"Pharmacogenetics"},{"key":"BF6500410_CR24","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMoa044503","volume":"352","author":"MJ Rieder","year":"2005","unstructured":"Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285\u20132293.","journal-title":"N Engl J Med"},{"key":"BF6500410_CR25","first-page":"234","volume":"43","author":"LS Kaminsky","year":"1993","unstructured":"Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA . Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993; 43: 234\u2013239.","journal-title":"Mol Pharmacol"},{"key":"BF6500410_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/00912700122010618","volume":"41","author":"JS Kim","year":"2001","unstructured":"Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino Jr JS . Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 2001; 41: 715\u2013722.","journal-title":"J Clin Pharmacol"},{"key":"BF6500410_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1365-2125.2002.01646.x","volume":"54","author":"U Yasar","year":"2002","unstructured":"Yasar U, Dahl ML, Christensen M, Eliasson E . Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 2002; 54: 183\u2013185.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500410_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/clpt.1984.256","volume":"36","author":"PJ Wedlund","year":"1984","unstructured":"Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA . Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773\u2013780.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500410_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajmg.1320570413","volume":"57","author":"I Cascorbi","year":"1995","unstructured":"Cascorbi I, Drakoulis N, Brockm\u00f6ller J, Maurer A, Sperling K, Roots I . Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581\u2013592.","journal-title":"Am J Hum Genet"},{"key":"BF6500410_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/ng1488","volume":"37","author":"KR Ahmadi","year":"2005","unstructured":"Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37: 84\u201389.","journal-title":"Nat Genet"},{"key":"BF6500410_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/ng0905-915","volume":"37","author":"R Walton","year":"2005","unstructured":"Walton R, Kimber M, Rockett K, Trafford C, Kwiatkowski D, Sirugo G . Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nat Genet 2005; 37: 915\u2013916; author reply 916.","journal-title":"Nat Genet"},{"key":"BF6500410_CR32","doi-asserted-by":"crossref","unstructured":"Anonymous. The International HapMap Project. Nature 2003; 426: 789\u2013796.","DOI":"10.1038\/nature02168"},{"key":"BF6500410_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00008571-199706000-00005","volume":"7","author":"CL Crespi","year":"1997","unstructured":"Crespi CL, Miller VP . The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203\u2013210.","journal-title":"Pharmacogenetics"},{"key":"BF6500410_CR34","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.bcp.2005.02.020","volume":"69","author":"DL Johnson","year":"2005","unstructured":"Johnson DL, Lewis BC, Elliot DJ, Miners JO, Martin LL . Electrochemical characterisation of the human cytochrome P450 CYP2C9. Biochem Pharmacol 2005; 69: 1533\u20131541.","journal-title":"Biochem Pharmacol"},{"key":"BF6500410_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0006-291X(02)02592-5","volume":"299","author":"U Yasar","year":"2002","unstructured":"Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299: 25\u201328.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6500410_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00228-005-0907-8","volume":"61","author":"M Depre","year":"2005","unstructured":"Depre M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005; 61: 341\u2013346.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500410_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0076-6879(96)72017-7","volume":"272","author":"JO Miners","year":"1996","unstructured":"Miners JO, Birkett DJ . Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol 1996; 272: 139\u2013145.","journal-title":"Methods Enzymol"},{"key":"BF6500410_CR38","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1124\/dmd.105.005272","volume":"33","author":"D Tomalik-Scharte","year":"2005","unstructured":"Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sorgel F, Klaassen T et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 2005; 33: 1859\u20131866.","journal-title":"Drug Metab Dispos"},{"key":"BF6500410_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1067\/mcp.2002.129321","volume":"72","author":"MG Scordo","year":"2002","unstructured":"Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R . Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702\u2013710.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500410_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clpt.2005.08.004","volume":"78","author":"HN Chaobal","year":"2005","unstructured":"Chaobal HN, Kharasch ED . Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther 2005; 78: 529\u2013539.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500410_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263\u2013265.","journal-title":"Bioinformatics"},{"key":"BF6500410_CR42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/genetics\/50.4.757","volume":"50","author":"RC Lewontin","year":"1964","unstructured":"Lewontin RC . The interaction of selection and linkage. Ii. Optimum models. Genetics 1964; 50: 757\u2013782.","journal-title":"Genetics"},{"key":"BF6500410_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2156-6-21","volume":"6","author":"E Zeggini","year":"2005","unstructured":"Zeggini E, Barton A, Eyre S, Ward D, Ollier W, Worthington J et al. Characterisation of the genomic architecture of human chromosome 17q and evaluation of different methods for haplotype block definition. BMC Genet 2005; 6: 21.","journal-title":"BMC Genet"},{"key":"BF6500410_CR44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/molbev\/msh266","volume":"22","author":"K Ding","year":"2005","unstructured":"Ding K, Zhou K, Zhang J, Knight J, Zhang X, Shen Y . The effect of haplotype-block definitions on inference of haplotype-block structure and htSNPs selection. Mol Biol Evol 2005; 22: 148\u2013159.","journal-title":"Mol Biol Evol"},{"key":"BF6500410_CR45","first-page":"152","volume":"9","author":"X Zhu","year":"2004","unstructured":"Zhu X, Zhang S, Kan D, Cooper R . Haplotype block definition and its application. Pac Symp Biocomput 2004; 9: 152\u2013163.","journal-title":"Pac Symp Biocomput"},{"key":"BF6500410_CR46","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1086\/379378","volume":"73","author":"M Stephens","year":"2003","unstructured":"Stephens M, Donnelly P . A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162\u20131169.","journal-title":"Am J Hum Genet"},{"key":"BF6500410_CR47","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/319501","volume":"68","author":"M Stephens","year":"2001","unstructured":"Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978\u2013989.","journal-title":"Am J Hum Genet"},{"key":"BF6500410_CR48","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1371\/journal.pbio.0030378","volume":"3","author":"PC Sabeti","year":"2005","unstructured":"Sabeti PC, Walsh E, Schaffner SF, Varilly P, Fry B, Hutcheson HB et al. The case for selection at CCR5-Delta32. PLoS Biol 2005; 3: e378.","journal-title":"PLoS Biol"},{"key":"BF6500410_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jchromb.2005.11.013","volume":"831","author":"S Engelhardt","year":"2006","unstructured":"Engelhardt S, Meineke I, Brockm\u00f6ller J . Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 831: 31\u201335.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"BF6500410_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL . Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503\u2013512.","journal-title":"J Pharmacokinet Biopharm"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/6500410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500410","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T20:47:11Z","timestamp":1736542031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6500410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,12]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,6,1]]}},"alternative-id":["BF6500410"],"URL":"https:\/\/doi.org\/10.1038\/sj.tpj.6500410","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,12]]},"assertion":[{"value":"17 March 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}